Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542

Viral entry inhibitors represent an emerging mode of therapy for human immunodeficiency virus type 1 (HIV-1) infection. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates. PRO 542 binds to the viral surface glycoprotein...

Deskribapen osoa

Xehetasun bibliografikoak

Argitaratua izan da:	Antimicrob Agents Chemother
Egile Nagusiak:	Jacobson, Jeffrey M., Israel, Robert J., Lowy, Israel, Ostrow, Nancy A., Vassilatos, Linda S., Barish, Melanie, Tran, Diep N. H., Sullivan, Brian M., Ketas, Thomas J., O'Neill, Tobias J., Nagashima, Kirsten A., Huang, Wei, Petropoulos, Christos J., Moore, John P., Maddon, Paul J., Olson, William C.
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	American Society for Microbiology (ASM) 2004
Gaiak:	Antiviral Agents
Sarrera elektronikoa:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC321533/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/14742190/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.2.423-429.2004
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!